Clinical trials
Phase 3 Pathologic Complete Response trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2009 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 5 |
| Active, not recruiting | 4 |
| Recruiting | 3 |
| Not yet recruiting | 1 |
| Terminated | 1 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Assistance Publique - Hôpitaux de Paris | 2 |
| Ming-Yuan Chen | 2 |
| 307 Hospital of PLA | 1 |
| AstraZeneca | 1 |
| Celgene | 1 |
| Henan Cancer Hospital | 1 |
| J. W. A. Burger | 1 |
| King Faisal Specialist Hospital & Research Center | 1 |
| Lund University Hospital | 1 |
| Michele Cavo | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pathologic Complete Response | 16 |
| Breast Neoplasms | 3 |
| Leukemia, Myeloid, Acute | 3 |
| Multiple Myeloma | 2 |
| Nasopharyngeal Carcinoma | 2 |
| Carcinoma, Ovarian Epithelial | 1 |
| Fallopian Tube Neoplasms | 1 |
| Lymphoma, Follicular | 1 |
| Neoplasms | 1 |
| Nephrosis, Lipoid | 1 |
Trials
Showing 76 to 16 of 16. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.